Art. -Nr.: HY-17512

Losartan

(Synonyms: DuP-753)

59 Cited Publications

Kundenbewertung

Based on 59 publication(s) in Google Scholar

Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC₅₀ of 20 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.41%
CAS. Nr.: 114798-26-4
Formel: C₂₂H₂₃ClN₆O
Molecular Weight:422.91

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Losartan Chemical Structure

CAS. Nr.: 114798-26-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (59)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC₅₀ of 20 nM.

IC₅₀ & Target

AT1 Receptor

Alle Angiotensin Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	40 nM Compound: DuP-753	In vitro inhibitory activity against rat Angiotensin II receptor, type 1 expressed in CHO cells In vitro inhibitory activity against rat Angiotensin II receptor, type 1 expressed in CHO cells	[PMID: 10579816]
CHO-K1	IC₅₀	28.6 nM Compound: Losartan	Displacement of [125I]Sar1Ile8-Ang2 from human AT1 receptor expressed in CHO-K1 cell membranes after 180 mins Displacement of [125I]Sar1Ile8-Ang2 from human AT1 receptor expressed in CHO-K1 cell membranes after 180 mins	[PMID: 26397395]
COS-7	IC₅₀	12.1 nM Compound: Cozaar	Displacement of 125I-[Sar1,Leu8] angiotensin-2 from rat type 1 angiotensin-2 receptor expressed in African green monkey COS7 cells after 24 hrs Displacement of 125I-[Sar1,Leu8] angiotensin-2 from rat type 1 angiotensin-2 receptor expressed in African green monkey COS7 cells after 24 hrs	[PMID: 26810314]
HASMC	IC₅₀	0.71 nM Compound: Losartan DuP-753	Inhibitory activity against Ang II-induced proliferation of human aortic smooth muscle cells in a dose dependent manner Inhibitory activity against Ang II-induced proliferation of human aortic smooth muscle cells in a dose dependent manner	[PMID: 8576904]
HEK293	IC₅₀	>250 μM Compound: losartan	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	6 nM Compound: losartan	Displacement of 125[I-Sar1-Ile8]ANG II from human AT1 receptor expressed in HEK293 membranes after 1 hr by gamma counting Displacement of 125[I-Sar1-Ile8]ANG II from human AT1 receptor expressed in HEK293 membranes after 1 hr by gamma counting	[PMID: 22889560]
HEK-293T	IC₅₀	2.4 μg/mL Compound: losartan	Antagonist activity at HA-tagged mouse AT1a angiotensin 2 receptor expressed in HEK293T cells assessed as decrease in angiotensin 2-induced intracellular calcium uptake Antagonist activity at HA-tagged mouse AT1a angiotensin 2 receptor expressed in HEK293T cells assessed as decrease in angiotensin 2-induced intracellular calcium uptake	[PMID: 18672373]

In Vitro

Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC₅₀) is 20 nM^[1]. Losartan (40 μM) affects I_SC but prevents the effect of ANGII on I_SC^[2]. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Losartan (0.6 g/L, p.o.) -treated Fbn1^C1039G/+ mice show a reduction in distal airspace caliber relative to placebo-treated Fbn1^C1039G/+ animals. The doses of losartan and propranolol are titrated to achieve comparable hemodynamic effects. Analysis of pSmad2 nuclear staining reveals that losartan antagonizes TGF-β signaling in the aortic wall of Fbn1^C1039G/+ mice. Losartan can improve disease manifestations in the lungs, an event that cannot plausibly relate to improved hemodynamics^[4]. Losartan (10 mg/kg, intraarterial injection) increases blood angiotensin levels four- to sixfold. Losartan (10 mg/kg, i.p.) increases plasma renin levels 100-fold; plasma angiotensinogen levels decreases to 24% of control; and plasma aldosterone levels are unchanged^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 114798-26-4
Appearance Solid
Molecular Weight 422.91
Formel C₂₂H₂₃ClN₆O
Color White to light yellow
SMILES

OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2
Synonyms

DuP-753
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (59)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyApoptosis AnalysisCell Migration/Invasion AssayIHCRT-PCRIFWB

Sort by:

Journal Impact Factor

Nat Commun

FGF4-FGFR1 signaling promotes podocyte survival and glomerular function to ameliorate diabetic kidney disease in male mice. [Abstract]

2025 Nov 25;16(1):10430. PMID: 41290710

Losartan purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 25;16(1):10430. [Abstract]

Blood glucose levels were significantly reduced in EMP-treated mice but remained unchanged with Losartan potassium (LOS, oral, 10 mg/kg/day) treatment.
Adv Sci (Weinh)

Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor Sizes. [Abstract]

2024 Dec 5:e2410360. PMID: 39639496
J Immunother Cancer

Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production. [Abstract]

2026 Mar 25;14(3):e012426. PMID: 41881499
J Immunother Cancer

Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade. [Abstract]

2024 Sep 6;12(9):e009327. PMID: 39244215

Losartan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]

Proliferation ability of MDA-MB-231 and HS578T cells in control and Losartan (10µM)-treated groups was assessed by colony formation assay.

Losartan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]

Apoptosis level of MDA-MB-231 and HS578T cells in control and Losartan (10µM)-treated groups was assessed by flow cytometry assay.

Losartan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]

Migration ability of MDA-MB-231 and HS578T cells in control and Losartan (10µM)-treated groups were assessed by Boyden chamber assay.

Losartan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]

Expression of COL1A1 in control and Losartan (10µM)-treated CAFs was assessed by qPCR and Western blotting assays.

Losartan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]

Expression of COL1A1 in control and Losartan (10µM)-treated CAFs was assessed by immunofluorescence assay.
Mol Biomed

G protein-coupled receptor 107 deficiency promotes development of diabetic nephropathy. [Abstract]

2025 Feb 11;6(1):10. PMID: 39932642
Adv Healthc Mater

Cascade-Responsive Nanoprodrug Disrupts Immune-Fibroblast Communications for Potentiated Cancer Mechanoimmunotherapy. [Abstract]

2025 Apr;14(11):e2500176. PMID: 40079115
Cell Death Dis

Sodium-glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. [Abstract]

2020 May 22;11(5):390. PMID: 32444604

Losartan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 May 22;11(5):390. [Abstract]

Both dapagliflozin and Losartan potassium treatment significantly reduced the urinary albumin levels at 12 weeks.

Losartan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 May 22;11(5):390. [Abstract]

Both dapagliflozin and Losartan potassium treatment significantly reduced the NGAL levels at 12 weeks.

Losartan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 May 22;11(5):390. [Abstract]

Morphological analysis revealed that glomerular tuft area , mesangial expansion, and mesangial matrix hyperplasia (fractional mesangial area, FMA), which were increased in diabetic mice, were also equally improved by dapagliflozin and Losartan potassium treatment.
Phytomedicine

Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways. [Abstract]

2024 Dec 3:136:156314. PMID: 39647467

Losartan purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Dec 3:136:156314. [Abstract]

The CCK-8 assay was performed to determine cell viability after Losartan potassium treatment under HG conditions for 48 h.

Losartan purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Dec 3:136:156314. [Abstract]

The kidney/body weight ratios demonstrated that both Losartan potassium and PHI exerted nephroprotective effects against DN, with H-PHI treatment exhibiting a greater effect.
Phytomedicine

Rutin alleviates EndMT by restoring autophagy through inhibiting HDAC1 via PI3K/AKT/mTOR pathway in diabetic kidney disease. [Abstract]

2023 Apr:112:154700. PMID: 36774842
Phytomedicine

Capsaicin ameliorates renal fibrosis by inhibiting TGF-β1-Smad2/3 signaling. [Abstract]

2022 Mar 21;100:154067. PMID: 35349832
Apoptosis

Targeting PAX8 sensitizes ovarian cancer cells to ferroptosis by inhibiting glutathione synthesis. [Abstract]

2024 Oct;29(9-10):1499-1514. PMID: 38853202
Clin Sci

Soluble (pro)renin receptor induces endothelial dysfunction and hypertension in mice with diet-induced obesity via activation of angiotensin II type 1 receptor. [Abstract]

2021 Mar 26;135(6):793-810. PMID: 33625485
J Transl Med

(Pro)renin receptor mediates tubular epithelial cell pyroptosis in diabetic kidney disease via DPP4-JNK pathway. [Abstract]

2024 Jan 5;22(1):26. PMID: 38183100
Oncogene

Stromal nicotinamide N-methyltransferase orchestrates the crosstalk between fibroblasts and tumour cells in oral squamous cell carcinoma: evidence from patient-derived assembled organoids. [Abstract]

2023 Apr;42(15):1166-1180. PMID: 36823377
Cell Rep

Calcium influx drives m6A-dependent RUNX1T1 splicing to promote adipogenic commitment. [Abstract]

2026 May 28;45(6):117471. PMID: 42213774
Clin Transl Med

DDR2-mediated autophagy inhibition contributes to angiotensin II-induced adventitial remodeling. [Abstract]

2025 Jun;15(6):e70361. PMID: 40468620
Clin Transl Med

Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma. [Abstract]

2023 Mar;13(3):e1213. PMID: 36855786
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Antioxidants (Basel)

Identification and Validation of the miR/RAS/RUNX2 Autophagy Regulatory Network in AngII-Induced Hypertensive Nephropathy in MPC5 Cells Treated with Hydrogen Sulfide Donors. [Abstract]

2024 Aug 7;13(8):958. PMID: 39199205
Int J Nanomedicine

Peritumoral implantation of hydrogel-containing nanoparticles and losartan for enhanced nanoparticle penetration and antitumor effect. [Abstract]

2018 Nov 13:13:7409-7426. PMID: 30519023
Cell Mol Life Sci

Rab26 promotes hypoxia-induced hyperproliferation of PASMCs by modulating the AT1R-STAT3-YAP axis. [Abstract]

2025 Nov 13;82(1):396. PMID: 41231254
Colloids Surf B Biointerfaces

A losartan-laden thermosensitive hydrogel scaffold to boost tumor chemo-immunotherapy via remodeling tumor mechanical microenvironment. [Abstract]

2025 Nov 25:259:115314. PMID: 41319609
Chem Biol Interact

Inhibition of AT1R/IP3/IP3R-mediated Ca2+ release protects against calcium oxalate crystals-induced renal oxidative stress. [Abstract]

2023 Sep 1:382:110636. PMID: 37454925
Int J Mol Sci

Role of Uric Acid in Vascular Remodeling: Cytoskeleton Changes and Migration in VSMCs. [Abstract]

2023 Feb 3;24(3):2960. PMID: 36769281
Biomolecules

Trametinib-Induced Epidermal Thinning Accelerates a Mouse Model of Junctional Epidermolysis Bullosa. [Abstract]

2023 Apr 25;13(5):740. PMID: 37238610
Biomolecules

Structure-Based Virtual Screening and Functional Validation of Potential Hit Molecules Targeting the SARS-CoV-2 Main Protease. [Abstract]

2022 Nov 25;12(12):1754. PMID: 36551182
Eur J Pharmacol

Angiotensin II-induced fibrosis is mediated by activation of FGFR1 pathway in renal epithelial cells: Attenuation by chimeric peptide. [Abstract]

2025 Dec 15:1009:178390. PMID: 41274591
Int Immunopharmacol

ADAM17 knockdown is more effective than AT1R blocker in alleviating diabetic cardiomyopathy through downregulating the RhoA-ROCK1 pathway. [Abstract]

2025 Sep 23:162:115168. PMID: 40633210
J Mol Cell Cardiol

Elevated KCa3.1 expression by angiotensin II via the ERK/NF-κB pathway contributes to atrial fibrosis. [Abstract]

2025 May:202:133-143. PMID: 40122157
Int Immunopharmacol

Anti-tumor effects of telmisartan in glioma-astrocyte non-contact co-cultures: A critical role of astrocytic IL-6-mediated paracrine growth promotion. [Abstract]

2024 Jul 19:139:112707. PMID: 39032472
Int Immunopharmacol

Telmisartan inhibits microglia-induced neurotoxic A1 astrocyte conversion via PPARγ-mediated NF-κB/p65 degradation. [Abstract]

2023 Oct:123:110761. PMID: 37544025
J Physiol

miR-22-3p in the rostral ventrolateral medulla promotes hypertension through inhibiting β-arrestin-1. [Abstract]

2024 Jan;602(2):317-332. PMID: 38152023
FASEB J

Mitochondrial Calcium Uniporter-Mediated Regulation of the SIRT3/GSK3β/β-Catenin Signaling Pathway in Vascular Remodeling. [Abstract]

2025 Jul 15;39(13):e70761. PMID: 40622073
FASEB J

Transactivation domain of Krüppel-like factor 15 negatively regulates angiotensin II-induced adventitial inflammation and fibrosis. [Abstract]

2019 May;33(5):6254-6268. PMID: 30776250
FASEB J

Angiotensin II increases angiogenesis by NF-κB-mediated transcriptional activation of angiogenic factor AGGF1. [Abstract]

2018 Sep;32(9):5051-5062. PMID: 29641288

Losartan purchased from MedChemExpress. Usage Cited in: FASEB J. 2018 Sep;32(9):5051-5062. [Abstract]

HUVECs are starved for 12 h, treated with 10 mg/mL (9.56 μM) of AngII with or without Losartan or PD123319 for 12 h, and are subsequently used for Western blot analysis.
Am J Physiol Heart Circ Physiol

Overexpression of the neuronal human (pro)renin receptor mediates angiotensin II-independent blood pressure regulation in the central nervous system. [Abstract]

2018 Mar 1;314(3):H580-H592. PMID: 29350998
Sci Rep

AT1 and AT2 receptors modulate renal tubular cell necroptosis in angiotensin II-infused renal injury mice. [Abstract]

2019 Dec 19;9(1):19450. PMID: 31857626
Toxicol Appl Pharmacol

Saikosaponin D protects against isoproterenol-induced kidney injury in rats by regulating the intrarenal renin-angiotensin system. [Abstract]

2026 Mar 27:511:117802. PMID: 41903810
Toxicol Appl Pharmacol

In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1. [Abstract]

2024 May:486:116945. PMID: 38688424
Front Physiol

Angiotensin II Stimulates the Proliferation and Migration of Lymphatic Endothelial Cells Through Angiotensin Type 1 Receptors. [Abstract]

2020 Sep 8;11:560170. PMID: 33013481
Am J Physiol Renal Physiol

Soluble (pro)renin receptor promotes the fibrotic response in renal proximal tubule epithelial cells in vitro via the Akt/β-catenin/Snail signaling pathway. [Abstract]

2020 Nov 1;319(5):F941-F953. PMID: 32865015
Kaohsiung J Med Sci

Forsythiaside A Alleviates Kidney Injury and Intestinal Epithelium Dysfunction in IgA Nephropathy by Inhibiting TLR4/NF-κB Signaling. [Abstract]

2025 Nov 28:e70144. PMID: 41313694
Toxicol Lett

Discovery of non-steroidal aldo-keto reductase 1D1 inhibitors through automated screening and in vitro evaluation. [Abstract]

2025 Apr:406:31-37. PMID: 39988211
J Pharmacol Sci

Sustained increased CaMKII phosphorylation is involved in the impaired regression of isoproterenol-induced cardiac hypertrophy in rats. [Abstract]

2020 Sep;144(1):30-42. PMID: 32665128
J Appl Toxicol

The Angiotensin II Receptor Antagonist Losartan Impairs Female Fertility in Rats: Potential Mediating Role of microRNA-129-1-3p. [Abstract]

2026 Jun 17. PMID: 42310910
J Orthop Surg Res

Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy. [Abstract]

2024 Feb 19;19(1):147. PMID: 38373964
Nefrologia

2023 Sep 6.
Gene

Calcitriol ameliorates renal injury with high-salt diet-induced hypertension by upregulating GLIS2 expression and AMPK/mTOR-regulated autophagy. [Abstract]

2022 Apr 30:820:146239. PMID: 35114278
Biochem Biophys Res Commun

Arginine vasopressin and angiotensin II coregulate Aquaporin 2 expression in M-1 cells. [Abstract]

2025 Jan:745:151256. PMID: 39740402
Rep Biochem Mol Biol

Signaling Pathway in the Osmotic Resistance Induced by Angiotensin II AT2 Receptor Activation in Human Erythrocytes. [Abstract]

2021 Jul;10(2):314-326. PMID: 34604421
Arch Biol Sci

2021 Jun.
bioRxiv

2026 Jun 19.
bioRxiv

Angiotensin AT1 Receptors Promote Age-Dependent Expansion of Presympathetic Networks in Spontaneously Hypertensive Rats. [Abstract]

2026 Jun 8:2026.06.03.729868. PMID: 42327208
bioRxiv

2026 Apr 7.
SSRN

2025 Nov 6.
Res Sq

2024 Jul 16.
Friedrich-Alexander University Erlangen-Nuremberg

2023 May 2.
Research Square Print

September 13th, 2022.
Oxid Med Cell Longev

Angiotensin II Induces Cardiac Edema and Hypertrophic Remodeling through Lymphatic-Dependent Mechanisms. [Abstract]

2022 Feb 18:2022:5044046. PMID: 35222798

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (236.46 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3646 mL

11.8228 mL

23.6457 mL

5 mM

0.4729 mL

2.3646 mL

4.7291 mL

10 mM

0.2365 mL

1.1823 mL

2.3646 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[3]

An MTT assay is used to measure cell proliferation and viability. For the assay, 5000 cells in 200 μL media per well are seeded in a 96 well plate. After overnight incubation to allow for cell attachment, the medium is removed by suction. MTT at 1 mg/mL concentration in serum-free medium is added and then incubated for 4 h at 37°C. After removal of MTT solution, 100 μL of DMSO is added to dissolve formazan crystals. Absorbance at 570 nm and at 600 nm as a reference is then measured using a microplate reader. The difference in absorbance is thus relative to the extent of cell survival.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Female Fbn1^C1039G/+ mice undergo timed matings with wild-type male mice. At 14.5d post-coitum, pregnant female Fbn1^C1039G/+ mice are treated with oral losartan (0.6 g/L in drinking water; n=10), propranolol (0.5 g/L; n=6) or placebo (n=12). Therapy is continued throughout lactation and after weaning until 10 months of age. Mice are sacrificed and examined using the techniques described above. Propranolol is used for comparison with losartan because β-adrenergic receptor blockade is the current albeit controversial standard of care to modulate abnormal growth of the aortic root in MFS. Beginning at 7 weeks of age, wild-type and Fbn1^C1039G/+ mice are treated with oral losartan (0.6 g/L in drinking water; n=5), propranolol (0.5 g/L; n=7) or placebo (n=10). Mice are continued on oral therapy for 6 months and then sacrificed.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12. [Content Brief]

[2]. Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014. [Content Brief]

[3]. Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31. [Content Brief]

[4]. Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21. [Content Brief]

[5]. Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3646 mL	11.8228 mL	23.6457 mL	59.1142 mL
	5 mM	0.4729 mL	2.3646 mL	4.7291 mL	11.8228 mL
	10 mM	0.2365 mL	1.1823 mL	2.3646 mL	5.9114 mL
	15 mM	0.1576 mL	0.7882 mL	1.5764 mL	3.9409 mL
	20 mM	0.1182 mL	0.5911 mL	1.1823 mL	2.9557 mL
	25 mM	0.0946 mL	0.4729 mL	0.9458 mL	2.3646 mL
	30 mM	0.0788 mL	0.3941 mL	0.7882 mL	1.9705 mL
	40 mM	0.0591 mL	0.2956 mL	0.5911 mL	1.4779 mL
	50 mM	0.0473 mL	0.2365 mL	0.4729 mL	1.1823 mL
	60 mM	0.0394 mL	0.1970 mL	0.3941 mL	0.9852 mL
	80 mM	0.0296 mL	0.1478 mL	0.2956 mL	0.7389 mL
	100 mM	0.0236 mL	0.1182 mL	0.2365 mL	0.5911 mL

Keywords

Losartan

59 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Losartan

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lipid Metabolite Compound Library

Nephrotoxicity Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Losartan

Alle Angiotensin Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (59)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Losartan Related Classifications

HY-17512 Related Classifications